SLC5A2 and chronic kidney disease: In several studies, the impact of SGLT2 inhibition on the burden of adverse events was large enough to affect cardiovascular mortality and all-cause mortality (Supplementary Table S1) (EMPAREG outcome [39], DAPA HF [28], CREDENCE [42], DAPA CKD [43]) to a degree that had not been observed since ACE-inhibition was introduced [8].